Why the study?
Does oral captopril 12.5 mg alter pharmacokinetics and neurohormonal biomarkers in patients with congestive heart failure?
Population
12 patients with congestive heart failure (divided into mild and serious cases)
Design
Case_series
Follow-up
6 hours
Authors
Loading...
Cautions against assuming standard PK in HF; single-case data leaves generalizability open.
Does oral captopril 12.5 mg alter pharmacokinetics and neurohormonal biomarkers in patients with congestive heart failure?
In patients with congestive heart failure, a 12.5 mg oral dose of captopril demonstrates extended peak time and half-life compared to normal subjects, and effectively modulates the renin-angiotensin-aldosterone system.
Nishida et al. (1990) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: